-transparent.png){kind=logo}
In recent years, several new classes of compounds have successfully been established in the treatment of cancer. They selectively inhibit disturbed signaling pathways or induce anti-tumor immune responses. These novel targeted cancer drugs show a favorable safety profile compared to conventional chemotherapeutic agents. The most important side effects of these anticancer agents include cutaneous reactions and occur in a time-dependant manner and show class-specific patterns. In this review article, we compare the cutaneous side effects of epidermal growth factor inhibitors (EGFRI), multikinase inhibitors (MKI), BRAF inhibitors (BRAFI), mTor inhibitors (mTorI) and immune checkpoint inhibitors and discuss severity-adapted management strategies.
L M Ehmann, and
H Schrumpf, and
P A Gerber, and
B Homey
June 1977,
Drug and therapeutics bulletin,
L M Ehmann, and
H Schrumpf, and
P A Gerber, and
B Homey
November 1984,
The Journal of pediatrics,
L M Ehmann, and
H Schrumpf, and
P A Gerber, and
B Homey
April 1989,
Wiener medizinische Wochenschrift (1946),
L M Ehmann, and
H Schrumpf, and
P A Gerber, and
B Homey
September 2006,
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,
L M Ehmann, and
H Schrumpf, and
P A Gerber, and
B Homey
November 2013,
Emergency medicine clinics of North America,
L M Ehmann, and
H Schrumpf, and
P A Gerber, and
B Homey
January 2014,
Inflammation & allergy drug targets,
L M Ehmann, and
H Schrumpf, and
P A Gerber, and
B Homey
January 1984,
Annales de medecine interne,
L M Ehmann, and
H Schrumpf, and
P A Gerber, and
B Homey
January 2012,
Expert opinion on drug safety,
L M Ehmann, and
H Schrumpf, and
P A Gerber, and
B Homey
January 2015,
Case reports in dentistry,
L M Ehmann, and
H Schrumpf, and
P A Gerber, and
B Homey
January 1958,
Revue de la tuberculose,
